SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …

There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …

Objective: To review glucose-lowering efficacy and changes in renal function associated
with sodium-glucose co-transporter 2 (SGLT2) inhibitors among patients with chronic kidney …

Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes mellitus (T2DM)
and is associated with poor clinical outcomes, including an increased risk of all-cause and …

Diabetic kidney disease (DKD) is a topic of increasing concern among clinicians involved in
the management of type 2 diabetes mellitus (T2DM). It is a progressive and costly …

Despite remarkable advances in diabetes care, patients with type 2 diabetes are still
burdened by higher morbidity and mortality than non-diabetic individuals. Atherosclerotic …

Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular
(CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus …

OBJECTIVE Randomized controlled trials have shown kidney-protective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …

Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …